DarioHealth Corp, the US-based digital therapeutics company, has filed a Form 424B5 with the US Securities and Exchange Commission for a mixed shelf offering of up to $75m (approximately £58m). The filing, made on 22 July 2026, allows the company to sell a combination of common stock, preferred stock, debt securities, warrants, and units over time.
The news weighed on DarioHealth's shares, which fell more than 8% in pre-market trading on the Nasdaq. Investors typically view shelf offerings as dilutive to existing shareholders, as they increase the number of shares outstanding. The company's stock had already declined around 30% year-to-date prior to the announcement, pressured by ongoing cash burn and a competitive digital health market.
DarioHealth stated that net proceeds from any sales under the shelf will be used for working capital, research and development, sales and marketing activities, and potential acquisitions or strategic investments. The company ended the first quarter of 2026 with approximately $20m in cash and equivalents, having posted a net loss of $8.5m for the period.
The digital health sector has faced headwinds in 2026, with many firms struggling to achieve profitability amid rising interest rates and tighter funding conditions. DarioHealth's platform provides personalised coaching and remote monitoring for chronic conditions such as diabetes, hypertension, and weight management. The company has been expanding its presence in the UK through partnerships with the NHS and private insurers.
Analysts at Canaccord Genuity noted that while the shelf filing provides financial flexibility, it also signals that DarioHealth may need additional capital to fund its growth plans. 'The company is burning cash at a rate that makes external financing necessary, but the dilution risk is a concern for retail investors,' one analyst commented.